User:Mr. Ibrahem/Tafamidis
Appearance
![]() | |
Clinical data | |
---|---|
Trade names | Vyndaqel, Vyndamax, others |
Other names | Tafamidis meglumine |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C14H7Cl2NO3 |
Molar mass | 308.11 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Tafamidis, sold under the brand names Vyndaqel among others, is a medication used to treat transthyretin-mediated amyloidosis.[5] It is taken by mouth.[6] It can be stopped after liver transplantation.[6]
Common side effects include abdominal pain, diarrhea, and infection.[6] Use during pregnancy is believed to harm the baby.[8] It works by stabilizing the protein transthyretin, thus decreasing the formulation amyloids.[4]
Tafamidis was approved for medical use in Europe in 2011 and the United States in 2019.[4][5] In the United Kingdom a month of 20 mg per day costs the NHS about £10,700 as of 2021.[6] This amount in the United States costs about 4,900 USD.[9]
References
[edit]- ^ a b "Vyndamax and Vyndaqel Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 July 2020. Archived from the original on 29 August 2021. Retrieved 16 August 2020.
- ^ "Vyndaqel 20 mg soft capsules - Summary of Product Characteristics". Electronic Medicines Compendium. Archived from the original on 2 April 2018. Retrieved 2 April 2018.
- ^ "Vyndaqel- tafamidis meglumine capsule, liquid filled Vyndamax- tafamidis capsule, liquid filled". DailyMed. 30 August 2019. Archived from the original on 1 April 2020. Retrieved 24 November 2019.
- ^ a b c "Vyndaqel EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019.
- ^ a b c d "Tafamidis Monograph for Professionals". Drugs.com. Archived from the original on 9 July 2021. Retrieved 7 August 2021.
- ^ a b c d e f BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 428. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ "Tafamidis Use During Pregnancy". Drugs.com. 6 September 2019. Archived from the original on 11 July 2021. Retrieved 16 August 2020.
- ^ "Tafamidis Use During Pregnancy". Drugs.com. Archived from the original on 11 July 2021. Retrieved 16 September 2021.
- ^ "Vyndaqel Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 16 September 2021.